Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive MyelofibrosisClaire Harrison, John Mascarenhas, Srđan Verstovšek et al.|Future Oncology|2022Cited by 40
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practiceShanti Amé, Jean‐Jacques Kiladjian, Fiorenza Barraco et al.|eJHaem|2023Cited by 6